What dose specification should be used for NRG radiation therapy trials, dose-to-medium or dose-to-water?

ConclusionThe present study showed large and systematic differences in doses calculated by AAA and Acuros Dm, m. Therefore, further investigation and clarification are needed about which dose reporting mode should be used.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Conditions:   Oropharynx Cancer;   Oropharynx Squamous Cell Carcinoma;   Carcinoma, Squamous Cell;   Carcinoma;   Oropharyngeal Neoplasms;   Neoplasms, Squamous Cell;   Neoplasms, Glandular and Epithelial;   Neoplasms by Histologic Type;   Pharyngeal Neoplasms Malignant and Unspecif ied;   Otorhinolaryngologic Neoplasms;   Head and Neck Neoplasms;   Neoplasms by Site;   Otorhinolaryngologic Diseases;   Pharyngeal Diseases...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Older patients undergoing radiation therapy (RT) for pelvic malignancies are at increased risk for pelvic fracture, which is associated with significant morbidity and mortality. RT techniques such as brachytherapy or intensity modulated RT (IMRT) allow for more conformal dose distributions, but it is not known whether the risk for pelvic fracture varies by RT modality.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
Conclusion: IMRT-based CCRT resulted in higher survival rates in patients with advanced clinical stages of TESCC (i.e., IIIA–IIIC), namely, clinical T3, clinical T4, or lymph node involvement.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
This Viewpoint discusses details of the Radiation Oncology Model, a 90-day episode-based alternative payment model proposed by the Centers for Medicare&Medicaid Services (CMS) intended to reduce inappropriate overuse of proton beam therapy, intensity-modulated radiation therapy (IMRT), and other expensive radiation oncology services.
Source: JAMA - Journal of the American Medical Association - Category: General Medicine Source Type: research
era S Abstract Adjuvant radiotherapy is a key treatment in early-stage breast cancer. The meta-analysis by the Early Breast Cancer Trialist's Collaborative Group (EBCTCG) has demonstrated a decreased risk of locoregional relapse and death after whole-breast radiotherapy. Prophylactic lymph nodes irradiation in breast cancer has also proven to be beneficial in several therapeutic trials. At a time when three-dimensional conformal radiotherapy has become the standard procedure and with the development of intensity-modulated radiation therapy, defining nodal volumes is essential and practices should be harmonized to ...
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research
Abstract The incidence of brain metastases is increasing and various treatment modalities exist for brain metastases. The aim of this study was to investigate the dosimetric quality and delivery efficiency of robotic radiosurgery (CyberKnife) for multiple brain metastases compared with C-arm linear accelerator (linac) based plans. C-arm linac based plans included intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT) and non-coplanar VMAT with 1, 3 and 5 non-coplanar arcs, respectively (NC1, NC3 and NC5). For 20 patients, six plans with a prescription dose of 30 Gy in three frac...
Source: Journal of Applied Clinical Medical Physics - Category: Physics Authors: Tags: J Appl Clin Med Phys Source Type: research
ConclusionsThe recommended phase 2 dose was palbociclib 125  mg/d for 21 days on and 7 days off with full standard dose of cetuximab and IMRT for locally advanced SCCHN. MTD was not achieved. The combination was well tolerated with promising preliminary efficacy. The expansion cohort of palbociclib 125 mg/d is currently accruing up to 15 locally advanced p16-negative SCCHN patients.Clinical trial identificationNCT#03024489.Legal entity responsible for the studyThe authors.FundingPfizer.DisclosureN. Ngamphaiboon: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Fund...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsReduced CTV margins and corresponding doses results in optimal long-term tumour control, with minimal late adverse events.Clinical trial identificationNCT03839602.Legal entity responsible for the studyChong Zhao.FundingNational Natural Science Foundation of China [No. 81872469]; Science and Technology Project of Guangdong Province [No. 2014A020212433].DisclosureM.L.K. Chua: Honoraria (institution), Advisory / Consultancy: Janssen, Astellas, Varian, Ferring Singapore and AstraZeneca; Research grant / Funding (institution), Structured research agreement/Research funding - Ferring Singapore, GenomeDx Biosciences, V...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsCoverage guidelines for IMRT, SRS, SABR, and PBT vary across 5 major insurance providers and may be substantially discordant compared with ASTRO coverage guidelines. There remain several specific areas where ongoing and future dialogues between ASTRO members, payers, and policymakers remain essential.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Proton Beam Therapy (PBT) is dosimetrically superior to Intensity Modulated Radiation Therapy (IMRT) in sparing critical organs in esophageal cancer (EC) patients (pts) treated with chemoradiation therapy (CRT). The extent to which better dosimetry translates into clinical benefit is not well established. We conducted a randomized trial to compare PBT to IMRT in terms of total toxicity burden (TTB) and progression free survival (PFS) time.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
More News: Cancer & Oncology | Clinical Trials | Intensity-Modulated Radiation Therapy | Radiation Therapy | Study